Cargando…
Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336665/ https://www.ncbi.nlm.nih.gov/pubmed/37448742 http://dx.doi.org/10.1016/j.xinn.2023.100461 |
| _version_ | 1785071257626083328 |
|---|---|
| author | Wang, Luxiang Zhang, Chunli Fan, Shuang Mo, Xiaodong Hu, Xiaoxia |
| author_facet | Wang, Luxiang Zhang, Chunli Fan, Shuang Mo, Xiaodong Hu, Xiaoxia |
| author_sort | Wang, Luxiang |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10336665 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103366652023-07-13 Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? Wang, Luxiang Zhang, Chunli Fan, Shuang Mo, Xiaodong Hu, Xiaoxia Innovation (Camb) Commentary Elsevier 2023-06-20 /pmc/articles/PMC10336665/ /pubmed/37448742 http://dx.doi.org/10.1016/j.xinn.2023.100461 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Commentary Wang, Luxiang Zhang, Chunli Fan, Shuang Mo, Xiaodong Hu, Xiaoxia Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_full | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_fullStr | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_full_unstemmed | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_short | Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy? |
| title_sort | treatment options for adult intermediate-risk aml patients in cr1: allo-hsct or chemotherapy? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336665/ https://www.ncbi.nlm.nih.gov/pubmed/37448742 http://dx.doi.org/10.1016/j.xinn.2023.100461 |
| work_keys_str_mv | AT wangluxiang treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy AT zhangchunli treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy AT fanshuang treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy AT moxiaodong treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy AT huxiaoxia treatmentoptionsforadultintermediateriskamlpatientsincr1allohsctorchemotherapy |